We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.65%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$342M
AUM Growth
-$111M
Cap. Flow
-$71.8M
Cap. Flow %
-21.01%
Top 10 Hldgs %
35.85%
Holding
99
New
15
Increased
34
Reduced
31
Closed
19

Top Buys

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$8.15M
2
IRTC icon
iRhythm Holdings
IRTC
+$5.39M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.36M
4
LEGN icon
Legend Biotech
LEGN
+$4.76M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.36M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.9M
3
AVTR icon
Avantor
AVTR
+$8.89M
4
DXCM icon
DexCom
DXCM
+$8.82M
5
DHR icon
Danaher
DHR
+$6.18M

Sector Composition

Rank Sector Weight
1 Healthcare 96.94%
2 Industrials 2.69%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
51
Veracyte
VCYT
$3.59B
$1.67M 0.49%
60,651
-1,613
-3% -$46.1K
ATRC icon
52
AtriCure
ATRC
$2.22B
$1.66M 0.48%
+25,236
New +$1.64M
AKYA
53
DELISTED
Akoya BioSciences
AKYA
$1.65M 0.48%
150,321
+25,321
+20% +$294K
TKNO icon
54
Alpha Teknova
TKNO
$397M
$1.65M 0.48%
119,468
+14,260
+14% +$224K
STRO icon
55
Sutro Biopharma
STRO
$353M
$1.64M 0.48%
19,985
-2,137
-10% -$203K
CNSY
56
Cerenome, Inc. Common Stock
CNSY
$25.5M
$1.53M 0.45%
+4,070
New +$1.55M
LNTH icon
57
Lantheus
LNTH
$6.57B
$1.4M 0.41%
+25,295
New +$949K
LFCR icon
58
Lifecore Biomedical
LFCR
$181M
$1.33M 0.39%
+115,316
New +$1.28M
CNCE
59
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.27M 0.37%
+377,399
New +$1.2M
TELA icon
60
TELA Bio
TELA
$32.3M
$1.26M 0.37%
108,504
+4,222
+4% +$51.1K
MRTX
61
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.25M 0.37%
15,236
+2,322
+18% +$237K
SCTL
62
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.21M 0.35%
671,817
+26,142
+4% +$45.3K
SIEN
63
DELISTED
Sientra, Inc.
SIEN
$1.18M 0.35%
53,186
+4,017
+8% +$110K
KNSA icon
64
Kiniksa Pharmaceuticals
KNSA
$6.1B
$1.18M 0.34%
118,247
+4,603
+4% +$48.8K
FMTX
65
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$1.16M 0.34%
124,310
+24,310
+24% +$259K
CTIC
66
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.05M 0.31%
+225,000
New +$671K
AXGN icon
67
Axogen
AXGN
$2.67B
$1.02M 0.3%
128,947
-77,651
-38% -$671K
ANAB icon
68
AnaptysBio
ANAB
$1.69B
$922K 0.27%
37,285
+1,452
+4% +$43.9K
PHAT icon
69
Phathom Pharmaceuticals
PHAT
$742M
$892K 0.26%
65,553
-11,928
-15% -$193K
ALLK
70
DELISTED
Allakos
ALLK
$867K 0.25%
+152,066
New +$983K
ZYME icon
71
Zymeworks
ZYME
$1.77B
$781K 0.23%
119,286
+77,661
+187% +$692K
OPNT
72
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$697K 0.2%
32,557
+1,266
+4% +$33.5K
MIRM icon
73
Mirum Pharmaceuticals
MIRM
$6.04B
$668K 0.2%
+30,354
New +$619K
SURF
74
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$615K 0.18%
209,148
-49,754
-19% -$174K
BLRX
75
BioLineRX
BLRX
$11.7M
$463K 0.14%
6,767
-3,948
-37% -$275K
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Parkman Healthcare Partners held 99 positions worth $342M, down 25% from $453M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners withdrew a net $71.8M in Q1 2022, closing 19 positions and reducing 31 holdings. Its most notable exit was HCA Healthcare, an estimated $13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Neurocrine Biosciences worth $5.93M.

  • Parkman Healthcare Partners's largest Q1 2022 buy was Neurocrine Biosciences: 63,234 shares worth $5.93M.
  • Parkman Healthcare Partners added most to Tenet Healthcare in Q1 2022, an estimated $8.15M increase.
  • Parkman Healthcare Partners's biggest Q1 2022 reduction was Avantor, cutting an estimated $8.89M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q1 2022, selling an estimated $13M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $342M portfolio in Q1 2022.
  • Parkman Healthcare Partners opened 15 new positions and closed 19 in Q1 2022.
  • Parkman Healthcare Partners's portfolio value fell 25% quarter-over-quarter to $342M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.